ANDREW WHELTON: Influence Statistics

ANDREW WHELTON

ANDREW WHELTON

Universal Clinical Research Center, Inc., Hunt Valley, MD, USA. huntvalley@aol.com | Department of Medicine, The Johns Hopkins University, Baltimore, Maryland | Canyon ...

ANDREW WHELTON: Expert Impact

Concepts for which ANDREW WHELTON has direct influence: Clinical pharmacologists , Patients thrombosis , Renal carbonic anhydrase , Argatroban patients , Metabolic alkalosis , Hit study , Thrombosis argatroban .

ANDREW WHELTON: KOL impact

Concepts related to the work of other authors for which for which ANDREW WHELTON has influence: Renal involvement , Porous silicon , Rheumatic diseases , Prostaglandin e1 , Contrastinduced nephropathy , Patient compliance , Bone cement .

KOL Resume for ANDREW WHELTON

Year
2010

Universal Clinical Research Center, Inc., Hunt Valley, MD, USA.

Department of Medicine, The Johns Hopkins University, Baltimore, Maryland

ScienceFirst, LLC, Cedar Knolls, New Jersey

2009

Clinical Research, Canyon Pharmaceuticals, Hunt Valley, MD, USA

2007

From the Division of Clinical Pharmacology, Rush University Medical Center, Chicago, Illinois; Universal Clinical Research Center, Inc; and The John Hopkins University School of Medicine, Baltimore, Maryland., From the Division of Clinical Pharmacology, Rush University Medical Center, Chicago, Illinois; Universal Clinical Research Center, Inc; and The John Hopkins University School of Medicine, Baltimore, Maryland.

2006

Universal Clinical Research Institute, Baltimore, MD

2005

Johns Hopkins University School of Medicine, Baltimore, Maryland; and Universal Clinical Research Center, Inc., Hunt Valley, Maryland.

2004

Adjunct Professor of Medicine Johns Hopkins University School of Medicine Director, Universal Clinical Research Center, Inc Hunt Valley, Maryland

NMRC, Lee Maltings, Prospect Row, Cork, Ireland

2002

Universal Clinical Research Center, Inc., Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

2001

Duke University Medical Center, Durham, NC; The Johns Hopkins University School of Medicine, Baltimore, MD; Schwarz Pharma AG, Monheim, Germany; Medizinische Einrichtungen der Heinrich-Heine-Universitat, Duesseldorf, Germany; and Kardiologie Martini Ziekenhuis, Groningen, The Netherlands.

Johns Hopkins University School of Medicine; Universal Clinical Research Center, Inc. (Whelton)

2000

University of Colorado School of Medicine, Denver, CO; and Johns Hopkins University School of Medicine, Baltimore, MD

1996

Division of Nephrology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Address for correspondence: The Johns Hopkins Hospital, Ross Building Suite 958, 720 Rutland Avenue, Baltimore, MD 21205, USA.

1994

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

1989

Respective President and Past President of the American College of Clinical Pharmacology, Wayne, Pennsylvania

1986

The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

1984

Associate Professor of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland.

1983

Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Md.

1980

From the O'Neill Research Laboratories of the Department of Medicine, The Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland.

1978

Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, U.S.A..

1974

Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, U.S.A..

Prominent publications by ANDREW WHELTON

KOL-Index: 9704 . BACKGROUND: Desirudin, a bivalent direct thrombin inhibitor (DTI), is approved by the US Food and Drug Administration for the prevention of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery. It became available in the United States in March 2010. OBJECTIVE: The goal of the present article was to provide an overview of the ...
Known for Hit Study | Argatroban Patients | Suspected Heparin | Induced Thrombocytopenia
KOL-Index: 6178 . Preexisting renal impairment is an all-encompassing risk factor for radiocontrast-associated nephrotoxicity. Renal impairment appears to be associated with the inadequate production of renal prostaglandins at the critical time of radiocontrast administration and for a variable time period afterward. We prospectively studied 130 patients with chronic renal insufficiency (serum creatinine > ...
Known for Serum Creatinine | Contrast Media | 48 Hours | Pge1 Groups
KOL-Index: 5677 . OBJECTIVE: To provide a review of the renal toxicity of disease-modifying antirheumatic drugs (DMARDs) currently used for the treatment of rheumatoid arthritis. METHODS: Papers in American and European medical journals related to renal toxicity of DMARDs used for the treatment of rheumatoid arthritis were reviewed. Specific DMARDs reviewed were cyclosporine, gold, D-penicillamine, ...
Known for Rheumatoid Arthritis | Antirheumatic Drugs | Etanercept Infliximab | Disease Modifying
KOL-Index: 3342 . The need for clinical pharmacology in research and education, drug development, and health care delivery is well known. However, a current profile of those working in the field is not available. The ACCP authorized a survey of clinical pharmacologists to provide such a profile. Members of the ACCP or ASCPT were solicited by mail with a self-assessment questionnaire. A response rate of 37% ...
Known for United States | Clinical Pharmacologists | Internal Medicine | Education Medical
KOL-Index: 2656 . Rofecoxib and celecoxib were the first cyclooxygenase-2 (COX-2)-specific inhibitors to be marketed as effective anti inflammatory agents. The results of several recent trials and a meta analysis of currently available studies all demonstrate a greater incidence of increased blood pressure, edema, and cardiovascular events in subjects treated with rofecoxib compared with celecoxib. As an ...
Known for Carbonic Anhydrase | Celecoxib Cyclooxygenase | Controlled Trial | Cardiovascular Events
KOL-Index: 2653 . The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal ...
Known for Hyperuricemia Gout | Renal Impairment | Uric Acid
KOL-Index: 2618 . An investigation of the fabrication of microporous silicon (MPS) layers as a material for the development of an electrolyte insulator semiconductor (EIS) capacitance sensor has been performed. The goal was to create a high surface area substrate for the immobilisation of biorecognition elements. Structural analysis of MPS layers as a function of key etch parameters, namely implant type (p ...
Known for Current Density | Ptype Silicon | Hydrofluoric Acid | Porous Layers
KOL-Index: 1989 . Nephrotoxicity and ototoxicity represent the most hazardous side effects of the clincial use of neomycin sulfate. Despite therapeutic restriction of the latter compound to topical, irrigant, and bowel sterilization use, serious toxicity is still encountered. A 69-year-old patient was recently treated by us for acute renal failure and total deafness induced as a result of intermittent ...
Known for Peritoneal Dialysis | Renal Function | Neomycin Sulfate | Therapeutic Irrigation
KOL-Index: 1011 . A precise numerical designation of the incidence of renal functional disorders induced by nonsteroidal anti-inflammatory drugs (NSAID) is difficult. This is in view of the heterogeneity of the populations who consume these agents and the variability in social customs that importantly influence the per capita ingestion of analgesic-anti-inflammatory drugs. Nonetheless, in most general ...
Known for Nonsteroidal Anti | Drugs Nsaid

Key People For Clinical Pharmacologists

Top KOLs in the world
#1
Simon R J Maxwell
clinical pharmacology prescribing errors medical students
#2
Jeffrey K ARONSON
adverse drug reactions medication errors clinical pharmacology
#3
Michael David RAWLINS†
united kingdom human liver alcoholic cirrhosis
#4
Folke Sjöqvist
northern ireland clinical pharmacology cytochrome p450
#5
Marcus M Reidenberg
clinical pharmacology pain control lupus erythematosus
#6
David J/INS; David
blood pressure arterial stiffness nitric oxide

Universal Clinical Research Center, Inc., Hunt Valley, MD, USA. huntvalley@aol.com | Department of Medicine, The Johns Hopkins University, Baltimore, Maryland | Canyon Pharmaceuticals, Inc., Hunt Valley, Maryland | ScienceFirst, LLC, Cedar Knolls, Ne